Stock 2315 BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Equities

2315

CNE100005D27

End-of-day quote Hong Kong S.E.
Other stock markets
 03:30:00 17/06/2024 am IST 		5-day change 1st Jan Change
7.49 CNY -7.19% Intraday chart for Biocytogen Pharmaceuticals (Beijing) Co., Ltd. -6.72% -37.48%
04/06 XtalPi Inc. announced that it has received CNY 337 million in funding from Shanghai Guosheng Investment Group, Biocytogen Pharmaceuticals Co., Ltd., FaaS Capital Longevity Limited and other investors CI
06/05 Biocytogen Enters into Evaluation and Potential Licensing Agreement with Biocopy for TCR-mimic Antibodies CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • The company has insufficient levels of profitability.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. Stock Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
-37.48% 38Cr -
MODERNA, INC. Stock Moderna, Inc.
+35.30% 5.28TCr
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-7.23% 3.89TCr
B
LONZA GROUP AG Stock Lonza Group AG
+35.54% 3.82TCr
A
CELLTRION, INC. Stock Celltrion, Inc.
-10.77% 2.68TCr
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.93% 2.62TCr
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-18.35% 1.99TCr
B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+36.48% 1.32TCr
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.36% 1.22TCr
C+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-2.58% 1.18TCr
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
-
MT Timing
-
LT Timing
-
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 2315 Stock
  4. Ratings Biocytogen Pharmaceuticals (Beijing) Co., Ltd.